Fig 1: Effects of IL-2/IL-15Rβ deficiency on MAIT1 and MAIT17 cells.a–f Eight–ten weeks old Il2/15rbf/f-Cd2iCre and littermate control Il2/15rbf/f or WT-Cd2iCre mice were analyzed for MAIT cells. a MAIT cell percentages in the indicated organs. b MAIT cell numbers in the indicated organs. c Stages 1–3 thymic MAIT cell numbers. d Representative FACS plots of T-bet and RORγt staining in liver CD24−CD44+ TCRβ+MR1-Tet+ MAIT cells. e, f T-bet+ MAIT1 and RORγt+ MAIT17 percentages (e) and numbers (f) in the indicated organs. Each connecting line represents one pair of control and IL-2/IL-15RβKO mice examined in one experiment. Data shown are pooled from or are representative of at least five experiments. g, h Analyses of lethally irradiated CD45.1+CD45.2+ recipient mice 2 months after being reconstituted with a mixture of BM cells from CD45.1+ WT and CD45.2+ Il2/15rbf/f-Cd2iCre mice at 1:1 ratio. g CD45.2+ IL-2/IL-15RβKO/CD45.1+ WT ratios of DP thymocytes and MAIT cells in the thymus, spleen, and liver. Each circle represents one recipient mouse. Bars represent mean ± SEM. h Percentages of MAIT1 and MAIT17 cells within CD45.2+ IL-2/IL-15RβKO and CD45.1+ WT MAIT cells. Each connecting line represents WT and IL-2/IL-15RβKO MAIT cells in one recipient mouse. Data shown are pooled from five experiments. Statistical significance is determined by two-tailed pairwise Student’s t test. P values of less than 0.05 are shown. Source data for all graphs are provided as a Source Data file.
Fig 2: YM101 antagonized the TGF-ß1-caused changes in the cytokine release. a The heatmap showing the effects of TGF-ß1 and YM101 on cytokine release during T cell activation. b–j YM101 reversed TGF-ß1-mediated alterations in cytokine release including IL-2, IL-4, IL-5, IL-6, IL-9, IL-13, IL-22, TNF-a, and IL-17A. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 denote the significant difference relative to YM101 treatment. a-TGF-ß: anti-TGF-ß, a-PD-L1: anti-PD-L1
Fig 3: YM101 counteracted the PD-1/PD-L1-mediated immunosuppression. a YM101 reversed the PD-1/PD-L1 axis-caused inhibition of IL-2 generation. The T cell activation assay was performed in the presence of exogeneous PD-L1 and YM101 or controls. b The CFSE dilution assays showed that YM101 antagonized the PD-1/PD-L1 axis-mediated proliferation inhibition in T cells. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 denote the significant difference relative to YM101 treatment. a-TGF-ß: anti-TGF-ß, a-PD-L1: anti-PD-L1
Fig 4: YM101 counteracted TGF-ß1-induced the differentiation of Tregs, proliferation inhibition, and apoptosis of T cells. a YM101 suppressed the differentiation of Tregs caused by TGF-ß1. Murine splenocytes were treated with plated-coated CD3, CD28, IL-2, TGF-ß1, and YM101 or controls. The results of flow cytometry showed the ratio of Treg in CD4+ T cells. b, c YM101 reversed the TGF-ß1-caused proliferation inhibition in T cells. d YM101 counteracted the TGF-ß1-caused alterations in cell cycle distribution in CTLL-2. e YM101 relieved the TGF-ß1-mediated apoptosis in CTLL-2. f YM101 reversed the TGF-ß1-caused alterations in cell cycle distribution in HT-2. g YM101 hedged the TGF-ß1-mediated apoptosis in HT-2. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 denote the significant difference relative to YM101 treatment. a-TGF-ß: anti-TGF-ß, a-PD-L1: anti-PD-L1
Fig 5: ICOS intrinsically promotes MAIT17 development.a–i Thymocytes and single-cell suspension of the indicated organs from 8–10 weeks old Icos−/− and control mice were stained for MAIT cells similarly to Fig. 1 directly (a, b, f) or after enrichment with MR1-Tet (c–e, g–i). a, c Dot plots show TCRβ and MR1-Tet staining in live gated Lin− cells before (a) and after (c) enrichment. b, d Scatter plots show MAIT cell percentages and numbers. e Stages 1–3 MAIT cell numbers in the thymus. f MAIT cell percentage and numbers in the indicated organs. g T-bet and RORγt expression in thymic MAIT cells. h Percentages and numbers of thymic MAIT1 and MAIT17 cells. i Percentages of IL-17A+ thymic and pLN MAIT cells after ex vivo PMA plus ionomycin stimulation for 4 h. Each circle and square represents one WT and ICOSKO mice, respectively. Data shown are representative of or pooled from four to eight experiments. j–l Analyses of irradiation chimeric CD45.1+ TCRJα18−/− mice reconstituted with CD45.1+CD45.2+ WT and CD45.2+ Icos−/− BM cells. j ICOSKO to WT ratios of the indicated populations of cells in the thymus from individual recipient mice. k Representative dot plots show CD45.1 and CD45.2 expression in CD122+ and CD122− stage 3 MAIT cells. l ICOSKO to WT ratios of MAIT cells in the indicated organs from individual recipient mice. Each circle represents one recipient mouse. Data shown are representative of or pooled from four experiments. Statistical significance is determined by two-tailed pairwise Student’s t test. P values of less than 0.05 are shown. Source data for all graphs are provided as a Source Data file.
Supplier Page from BioLegend for LEGENDplex™ MU Th Cytokine Panel (12-plex) w/ VbP V03